Restricted accessResearch articleFirst published online 2013-10
Identification of Potential Lung Cancer Biomarkers by Liquid Chromatography Tandem Mass Spectrometry-Based Proteomics Analysis of Secretomes of Two Lung Cancer Cell Lines
A label-free nano-liquid chromatography tandem mass spectrometry proteomics analysis on the conditioned media (CM) of two lung cancer cell lines of different histological backgrounds to identify secreted or membrane-bound proteins as novel lung cancer biomarkers was performed. Five hundred and seventy seven proteins were identified and 38% of them were classified as extracellular or membrane-bound. For the search of potential biomarkers of lung cancer a series of selection criteria were proposed. We detected known or putative lung cancer markers. In addition, 40 novel proteins were identified, whose role as biomarkers of lung cancer should be explored further.
SharifzadehS.OwjiS.M.PezeshkiA.M.Malek-HoseiniZ.KumarP.V.GhayumiS.M.GhaderiA., “Establishment and characterization of a human large cell lung cancer cell line with neuroendocrine differentiation”, Pathol. Oncol. Res.10(4), 225 (2004). doi: 10.1007/BF03033765
4.
TannerN.T.PastisN.J.ShermanC.SimonG.R.LewinD.SilvestriG.A., “The role of molecular analyses in the era of personalized therapy for advanced NSCLC”, Lung Cancer76(2), 131 (2012). doi: 10.1016/j.lungcan.2011.11.013
5.
StatesD.J.OmennG.S.BlackwellT.W.FerminD.EngJ.SpeicherD.W.HanashS.M., “Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study”, Nat. Biotechnol.24(3), 333 (2006). doi: 10.1038/nbt1183
6.
XiaoT.YingW.LiL.HuZ.MaY.JiaoL.MaJ.CaiY.LinD.GuoS.HanN.DiX.LiM.ZhangD.SuK.YuanJ.ZhengH.GaoM.HeJ.ShiS.LiW.XuN.ZhangH.LiuY.ZhangK.GaoY.QianX.ChengS., “An approach to studying lung cancer-related proteins in human blood”, Mol. Cell. Proteomics5, 1480 (2005). doi: 10.1074/mcp.M500055-MCP200
7.
LouX.XiaoT.ZhaoK.WangH.ZhengH.LinD.LuY.GaoY.ChengS.LiuS.XuN., “Cathepsin D is secreted from M-BE cells: Its potential role as a biomarker of lung cancer”, J. Proteome Res.6(3), 1083 (2007). doi: 10.1021/pr060422t
8.
HuangL.J.ChenS.X.HuangY.LuoW.J.JiangH.H.HuQ.H.ZhangP.F.YiH., “Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum marker of non-small cell lung cancer”, Lung Cancer54(1), 87 (2006). doi: 10.1016/j.lungcan.2006.06.011
9.
WangC.L.WangC.I.LiaoP.C.ChenC.D.LiangY.ChuangW.Y.TsaiY.H.ChenH.C.ChangY.S.YuJ.S.WuC.C.YuC.J., “Discovery of retinoblastoma-associated binding protein 46 as a novel prognostic marker for distant metastasis in nonsmall cell lung cancer by combined analysis of cancer cell secretome and pleural effusion proteome”, J. Proteome Res.8(10), 4428 (2009). doi: 10.1021/pr900160h
10.
PlanqueC.KulasingamV.SmithC.R.ReckampK.GoodglickL.DiamandisE.P., “Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines”, Mol. Cell. Proteomics8(12), 2746 (2009). doi: 10.1074/mcp.M900134-MCP200
11.
PavlouM.P.DiamandisE.P., “The cancer cell secretome: A good source for discovering biomarkers?”, J. Proteomics73(10), 1896 (2010). doi: 10.1016/j.jprot.2010.04.003
12.
MartosellaJ.ZolotarjovaN.LiuH.NicolG.BoyesB.E., “Reversed-phase high-performance liquid chromatographic prefractionation of immunodepleted human serum proteins to enhance mass spectrometry identification of lower-abundant proteins”, J. Proteome Res.4(5), 1522 (2005). doi: 10.1021/pr050088l
13.
ShevchenkoV.E.KovalevS.V.ArnotskayaN.E.ZborovskayaI.B.AkhmedovB.B.PolotskiiB.E.KostinA.U.MoukeriaA.F.ZaridzeD.G.DavidovM.I., “Human blood plasma proteome mapping for search of potential markers of the lung squamous cell carcinoma”, Eur. J. Mass Spectrom.19(2), 123 (2013). doi: 10.1255/ejms.1220
14.
MathivananS.JiH.SimpsonR.J., “Exosomes: Extracellular organelles important in 592 intercellular communication”, J. Proteomics73(10), 1907 (2010). doi: 10.1016/j.jprot.2010.06.006
15.
MakridakisM.VlahouA., “Secretome proteomics for discovery of cancer biomarkers”, J. Proteomics73(12), 2291 (2010). doi: 10.1016/j.jprot.2010.07.001
16.
KulasingamV.DiamandisE.P., “Tissue culture-based breast cancer biomarker discovery platform”, Int. J. Cancer123(9), 2007 (2008). doi: 10.1002/ijc.23844
17.
Schaaij-VisserT.B.de WitM.LamS.W.JiménezC.R., “The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context”, Biochim. Biophys. Acta1834(11), 2242 (1834) (2013). doi: 10.1016/j.bbapap.2013.01.029
18.
KimJ.E.KooK.H.KimY.H.SohnJ.ParkY.G., “Identification of potential lung cancer biomarkers using an in vitro carcinogenesis model”, Exp. Mol. Med.40(6), 709 (2008). doi: 10.3858/emm.2008.40.6.709
19.
KimS.W.CheonK.KimC.H.YoonJ.H.HawkeD.H.KobayashiR.PrudkinL.WistubaI.I.LotanR.HongW.K.KooJ.S., “Proteomics-based identification of proteins secreted in apical surface fluid of squamous metaplastic human tracheobronchial epithelial cells cultured by three-dimensional organotypic air–liquid interface method”, Cancer Res.67(14), 6565 (2007). doi: 10.1158/0008-5472.CAN-06-2783
20.
WuC.C.HsuC.W.ChenC.D.YuC.J.ChangK.P.TaiD.I.LiuH.P.SuW.H.ChangY.S.YuJ.S., “Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas”, Mol. Cell. Proteomics9(6), 1100 (2010). doi: 10.1074/mcp.M900398-MCP200
21.
LuoX.LiuY.WangR.HuH.ZengR.ChenH., “A high-quality secretome of A549 cells aided the discovery of C4b-binding protein as a novel serum biomarker for non-small cell lung cancer”, J. Proteomics74(4), 528 (2011). doi: 10.1016/j.jprot.2011.01.011
22.
RhoJ.H.RoehrlM.H.WangJ.Y., “Tissue proteomics reveals differential and compartment-specific expression of the homologs transgelin and transgelin-2 in lung adenocarcinoma and its stroma”, J. Proteome Res.8(12), 5610 (2009). doi: 10.1021/pr900705r
23.
UptonM.P.HirohashiS.TomeY.MiyazawaN.SuemasuK.ShimosatoY., “Expression of vimentin in surgically resected adenocarcinomas and large cell carcinomas of lung”, Am. J. Surg. Pathol.10(8), 560 (1986). doi: 10.1097/00000478-198608000-00006
24.
SunS.PoonR.T.LeeN.P.YeungC.ChanK.L.NgI.O.DayP.J.LukJ.M., “Proteomics of hepatocellular carcinoma: Serum vimentin as a surrogate marker for small tumors (< or = 2 cm)”, J. Proteome Res.9(4), 1923 (2010). doi: 10.1021/pr901085z
25.
ChengD.LiangB.LiY., “Serum vascular endothelial growth factor (VEGF-C) as a diagnostic and prognostic marker in patients with ovarian cancer”, PLOS ONE8(2), e55309 (2013). doi: 10.1371/journal.pone.0055309
26.
PatelP.BaliseR.SrinivasS., “Variations in normal serum alpha-fetoprotein (AFP) levels in patients with testicular cancer on surveillance”, Onkologie35(10), 588 (2012). doi: 10.1159/000342695
27.
MezzapelleR.MiglioU.RenaO.PaganottiA.AllegriniS.AntonaJ.MolinariF.FrattiniM.MongaG.AlabisoO.BoldoriniR., “Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma”, Br. J. Cancer108(8), 1743 (2013). doi: 10.1038/bjc.2013.130
28.
XueF.WangL.ZhangM.CaiL., “Clinical significance of detection of serum values of neuron specific enolase before and after treatment for small cell lung cancer”, Zhongguo Fei Ai Za Zhi14, 723 (2011).
29.
YanagawaT.ShinozakiT.WatanabeH.SaitoK.RazA.TakagishiK., “Vascular endothelial growth factor-D is a key molecule that enhances lymphatic metastasis of soft tissue sarcomas”, Exp. Cell Res.318(7), 800 (2012). doi: 10.1016/j.yexcr.2012.01.024
30.
SepportaM.V.TumminelloF.M.FlandinaC.CrescimannoM.GiammancoM.La GuardiaM.di MajoD.LetoG., “Follistatin as potential therapeutic target in prostate cancer”, Target Oncol. 1 March. [Epub ahead of print] (2013).doi: 10.1007/s11523-013-0268-7
31.
WajapeyeeN.KapoorV.MahalingamM.GreenM.R., “Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines”, Mol. Cancer Ther.8(11), 3009 (2009). doi: 10.1158/1535-7163.MCT-09-0470
32.
JinushiM.NakazakiY.CarrascoD.R.DraganovD.SoudersN.JohnsonM.MihmM.C.DranoffG., “Milk fat globule EGF-8 promotes melanoma progression through coordinated Akt and twist signaling in the tumor microenvironment”, Cancer Res.68(21), 8889 (2008). doi: 10.1158/0008-5472.CAN-08-2147
SalamaI.MaloneP.S.MihaimeedF.JonesJ.L., “A review of the S100 proteins in cancer”, Eur. J. Surg. Oncol.34(4), 357 (2008). doi: 10.1016/j.ejso.2007.04.009
35.
TianT.HaoJ.XuA.HaoJ.LuoC.LiuC.HuangL.XiaoX.HeD., “Determination of metastasis-associated proteins in non-small cell lung cancer by comparative proteomic analysis”, Cancer Sci.98(8), 1265 (2007). doi: 10.1111/j.1349-7006.2007.00514.x
36.
SingerS.MalzM.HerpelE.WarthA.BissingerM.KeithM.MuleyT.MeisterM.HoffmannH.PenzelR.GdyniaG.EhemannV.SchnabelP.A.KunerR.HuberP.SchirmacherP.BreuhahnK., “Coordinated expression of stathmin family members by far upstream sequence element binding protein-1 increases motility in non-small cell lung cancer”, Cancer Res.69(6), 2234 (2009). doi: 10.1158/0008-5472.CAN-08-3338
37.
ZangD.LiX.ZhangL., “14-3-3 ξ overexpression and abnormal β-catenin expression are associated with poor differentiation and progression in stage I non-small cell lung cancer”, Clin. Exp. Med.10(4), 221 (2010). doi: 10.1007/s10238-009-0089-2
38.
Pereira-FacaS.R.KuickR.PuravsE.ZhangQ.KrasnoselskyA.L.PhanstielD.QiuJ.MisekD.E.HindererR.TammemagiM.LandiM.T.CaporasoN.PfeifferR.EdelsteinC.GoodmanG.BarnettM.ThornquistM.BrennerD.HanashS.M., “Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer”, Cancer Res.67(24), 12000 (2007). doi: 10.1158/0008-5472.CAN-07-2913
